2-bromo-N-(3,5-dibromopyrazin-2-yl)acetamide | 1228013-80-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-bromo-N-(3,5-dibromopyrazin-2-yl)acetamide
• CAS: 1228013-80-6
• 化学式: C₆H₄Br₃N₃O
• 分子量: 373.829
• InChiKey: KCXHWKVIHRVLDF-UHFFFAOYSA-N

物化性质

• 沸点：
  436.8±45.0 °C(Predicted)
• 密度：
  2.419±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-N-(3,5-dibromopyrazin-2-yl)acetamide 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 6-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-4-(2-methoxyethyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
  参考文献：
  名称：

  Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223

  摘要：

  We report here the synthesis and structure-activity relationship (SAR) of a novel series of mammalian target of rapamycin (mTOR) kinase inhibitors. A series of 4,6- or 1,7-disubstituted-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-ones were optimized for in vivo efficacy. These efforts resulted in the identification of compounds with excellent mTOR kinase inhibitory potency, with exquisite kinase selectivity over the related lipid kinase PI3K. The improved PK properties of this series allowed for exploration of in vivo efficacy and ultimately the selection of CC-223 for clinical development.

  DOI：

  10.1021/acs.jmedchem.5b00626
• 作为产物：
  描述：

  溴代乙酸酐 、 2-氨基-3,5-二溴吡嗪 在 水 、 乙酸乙酯 、 magnesium sulfate 作用下， 以 乙腈 为溶剂， 以to afford the title compound (3.78 g, 10.1 mmol, 85% yield)的产率得到2-bromo-N-(3,5-dibromopyrazin-2-yl)acetamide
  参考文献：
  名称：

  METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS

  摘要：

  本文提供了制备具有以下结构的杂环芳基化合物的方法：其中R1-R4如本文所定义。这些杂环芳基化合物可用于治疗或预防癌症、炎症疾病、免疫疾病、神经退行性疾病、糖尿病、肥胖症、神经系统疾病、年龄相关疾病或心血管疾病。

  公开号：

  US20130245254A1

文献信息

• [EN] MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY<br/>[FR] INHIBITEURS DE mTOR KINASE ET LEUR EMPLOI DANS LES CAS D'INDICATIONS ONCOLOGIQUES ET POUR DES MALADIES EN RAPPORT AVEC LA VOIE mTOR/P13K/AKT
  申请人：SIGNAL PHARM LLC

  公开号：WO2010062571A1

  公开（公告）日：2010-06-03

  Provided herein are Heteroaryl Compounds having the following structure: R2 N (I) or (II) wherein R1 -R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供具有以下结构的杂环芳基化合物：R2 N（I）或（II），其中R1-R4如本文所定义，包含有效量杂环芳基化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、神经退行性疾病、糖尿病、肥胖症、神经系统疾病、与年龄相关的疾病或心血管疾病的方法，包括向需要的患者施用有效量的杂环芳基化合物。
• [EN] METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS<br/>[FR] PROCÉDÉS DE SYNTHÈSE ET DE PURIFICATION DE COMPOSÉS HÉTÉROARYLES
  申请人：SIGNAL PHARM LLC

  公开号：WO2011053518A1

  公开（公告）日：2011-05-05

  Provided herein are methods to prepare Heteroaryl Compounds having the following structure: Forumula (I) or Formula (II): wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.

  本文提供了制备具有以下结构的杂环芳基化合物的方法：Forumula（I）或Formula（II）：其中R1-R4如本文所定义。这些杂环芳基化合物可用于治疗或预防癌症、炎症性疾病、免疫性疾病、神经退行性疾病、糖尿病、肥胖症、神经系统疾病、老年病或心血管疾病。
• mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
  申请人：Perrin-Ninkovic Sophie

  公开号：US20100216781A1

  公开（公告）日：2010-08-26

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 -R 4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供了以下结构的杂环芳基化合物：其中R1-R4的定义如下，包含有效量的杂环芳基化合物的组合物以及治疗或预防癌症、炎症性疾病、免疫性疾病、神经退行性疾病、糖尿病、肥胖症、神经系统疾病、与年龄相关的疾病或心血管疾病的方法，包括向需要此类治疗的患者施用有效量的杂环芳基化合物。
• PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
  申请人：Perrin-Ninkovic Sophie

  公开号：US20120059164A1

  公开（公告）日：2012-03-08

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 -R 4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供具有以下结构的杂环芳基化合物：其中R1-R4如本文所定义，包括有效量的杂环芳基化合物的组合物以及治疗或预防癌症、炎症病症、免疫病症、神经退行性疾病、糖尿病、肥胖症、神经系统疾病、与年龄相关的疾病或心血管病症的方法，包括向需要该药物的患者施用有效量的杂环芳基化合物。
• Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
  申请人：Signal Pharmaceuticals, LLC

  公开号：US08110578B2

  公开（公告）日：2012-02-07

  Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供具有以下结构的杂环芳基化合物：其中，R1-R4如本文所定义，包含有效量的杂环芳基化合物的组合物以及治疗或预防癌症、炎症疾病、免疫疾病、神经退行性疾病、糖尿病、肥胖症、神经系统疾病、老年疾病或心血管疾病的方法，包括向需要此类治疗的患者施用有效量的杂环芳基化合物。